These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

356 related articles for article (PubMed ID: 22161861)

  • 21. Inhibition of p70S6K1 Activation by Pdcd4 Overcomes the Resistance to an IGF-1R/IR Inhibitor in Colon Carcinoma Cells.
    Zhang Y; Wang Q; Chen L; Yang HS
    Mol Cancer Ther; 2015 Mar; 14(3):799-809. PubMed ID: 25573956
    [TBL] [Abstract][Full Text] [Related]  

  • 22. miR-455-5p suppresses hepatocellular carcinoma cell growth and invasion via IGF-1R/AKT/GLUT1 pathway by targeting IGF-1R.
    Hu Y; Yang Z; Bao D; Ni JS; Lou J
    Pathol Res Pract; 2019 Dec; 215(12):152674. PubMed ID: 31732382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
    Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
    Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells.
    Rowzee AM; Ludwig DL; Wood TL
    Endocrinology; 2009 Aug; 150(8):3611-9. PubMed ID: 19406949
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Inhibition of hepatocellular carcinoma cell growth by an anti-insulin-like growth factor-I receptor monoclonal antibody.
    Yue L; Wang Y; Wang H; Gao H; Liang J; Sui A; Xiang J; Zhou F; Xu C; Zhao W; Liang W; Yao R
    Oncol Rep; 2012 Oct; 28(4):1453-60. PubMed ID: 22895605
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Insulin-like growth factor-1 receptor and ErbB kinase inhibitor combinations block proliferation and induce apoptosis through cyclin D1 reduction and Bax activation.
    Wilsbacher JL; Zhang Q; Tucker LA; Hubbard RD; Sheppard GS; Bamaung NY; Fidanze SD; Wang GT; Hu X; Davidsen SK; Bell RL; Wang J
    J Biol Chem; 2008 Aug; 283(35):23721-30. PubMed ID: 18559346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The insulin-like growth factor 1 pathway is a potential therapeutic target for low-grade serous ovarian carcinoma.
    King ER; Zu Z; Tsang YT; Deavers MT; Malpica A; Mok SC; Gershenson DM; Wong KK
    Gynecol Oncol; 2011 Oct; 123(1):13-8. PubMed ID: 21726895
    [TBL] [Abstract][Full Text] [Related]  

  • 28. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
    Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
    Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MiR-505 suppressed the growth of hepatocellular carcinoma cells via targeting IGF-1R.
    Ren L; Yao Y; Wang Y; Wang S
    Biosci Rep; 2019 Jul; 39(7):. PubMed ID: 31160483
    [TBL] [Abstract][Full Text] [Related]  

  • 30. IR-A/IGF-1R-mediated signals promote epithelial-mesenchymal transition of endometrial carcinoma cells by activating PI3K/AKT and ERK pathways.
    Wang C; Su K; Zhang Y; Zhang W; Zhao Q; Chu D; Guo R
    Cancer Biol Ther; 2019; 20(3):295-306. PubMed ID: 30426831
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Autocrine insulin-like growth factor-II stimulation of tumor cell migration is a progression step in human hepatocarcinogenesis.
    Nussbaum T; Samarin J; Ehemann V; Bissinger M; Ryschich E; Khamidjanov A; Yu X; Gretz N; Schirmacher P; Breuhahn K
    Hepatology; 2008 Jul; 48(1):146-56. PubMed ID: 18537183
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Restoration of klotho expression induces apoptosis and autophagy in hepatocellular carcinoma cells.
    Shu G; Xie B; Ren F; Liu DC; Zhou J; Li Q; Chen J; Yuan L; Zhou J
    Cell Oncol (Dordr); 2013 Apr; 36(2):121-9. PubMed ID: 23248036
    [TBL] [Abstract][Full Text] [Related]  

  • 33. IGF-I receptor as an emerging potential molecular-targeted for hepatocellular carcinoma in vitro and in vivo.
    Yao M; Wang L; Yang J; Yan X; Cai Y; Yao D
    Tumour Biol; 2016 Nov; 37(11):14677-14686. PubMed ID: 27623941
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Dual IGF-I/II-neutralizing antibody MEDI-573 potently inhibits IGF signaling and tumor growth.
    Gao J; Chesebrough JW; Cartlidge SA; Ricketts SA; Incognito L; Veldman-Jones M; Blakey DC; Tabrizi M; Jallal B; Trail PA; Coats S; Bosslet K; Chang YS
    Cancer Res; 2011 Feb; 71(3):1029-40. PubMed ID: 21245093
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The insulin-like growth factor I receptor/insulin receptor tyrosine kinase inhibitor PQIP exhibits enhanced antitumor effects in combination with chemotherapy against colorectal cancer models.
    Flanigan SA; Pitts TM; Eckhardt SG; Tentler JJ; Tan AC; Thorburn A; Leong S
    Clin Cancer Res; 2010 Nov; 16(22):5436-46. PubMed ID: 20943761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The insulin-like growth factor-I receptor inhibitor picropodophyllin-induced selective apoptosis of hepatocellular carcinoma cell through a caspase-dependent mitochondrial pathway.
    E C; Li J; Shao D; Zhang D; Pan Y; Chen L; Zhang X
    Oncol Res; 2013; 21(2):103-10. PubMed ID: 24406046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Insulin-like growth factor-1 receptor acts as a growth regulator in synovial sarcoma.
    Friedrichs N; Küchler J; Endl E; Koch A; Czerwitzki J; Wurst P; Metzger D; Schulte JH; Holst MI; Heukamp LC; Larsson O; Tanaka S; Kawai A; Wardelmann E; Buettner R; Pietsch T; Hartmann W
    J Pathol; 2008 Dec; 216(4):428-39. PubMed ID: 18855347
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting the insulin-like growth factor-1 receptor to overcome bortezomib resistance in preclinical models of multiple myeloma.
    Kuhn DJ; Berkova Z; Jones RJ; Woessner R; Bjorklund CC; Ma W; Davis RE; Lin P; Wang H; Madden TL; Wei C; Baladandayuthapani V; Wang M; Thomas SK; Shah JJ; Weber DM; Orlowski RZ
    Blood; 2012 Oct; 120(16):3260-70. PubMed ID: 22932796
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Promotion of Insulin-like growth factor II in cell proliferation and epithelial-mesenchymal transition in hepatocellular carcinoma.
    Ma Y; Chen Y; Chen L; Liu Z; Ieong ML; Gao F; Huang W
    J Cancer Res Ther; 2018; 14(4):844-850. PubMed ID: 29970663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The regulation of proliferation and apoptosis in hepatocellular carcinoma via insulin-like growth factor 1 receptor.
    Xu G; Chu J; Shi Y; Huang L; Fu J
    Growth Horm IGF Res; 2022 Oct; 66():101499. PubMed ID: 36084573
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.